The acquisition of Radcal by IBA will support Radcal’s continued growth in the dosimetry and quality assurance market, while further strengthening IBA’s medical imaging quality assurance offering and its presence in the US market
IBA supplies proton therapy equipment and services. (Credit: Dmitriy Gutarev from Pixabay)
Belgian medical technology company Ion Beam Applications (IBA) has agreed to acquire all the assets of Radcal, a US-based provider of diagnostic X-ray measurements.
Radcal has introduced the first X-ray instrument that provides complete measures of X-ray dose with the ability to interchange sensors without compromising in accuracy.
The company’s initial products are still in active use around the world, its Gold Standard Ion Chamber continues to top the X-ray industry, and systems generated around $6m last year.
The business combination with IBA is expected to support Radcal’s continued growth in the dosimetry and quality assurance market.
Also, the transaction, which is expected to be closed on 29 February 2024, will enhance its footprint in the key US markets and expand its product offering beyond OEM.
IBA CEO Olivier Legrain said: “This acquisition strengthens our position as a global leader in Medical Imaging Dosimetry and Quality Assurance, complementing our leading position in the radiotherapy market and diversifying our revenue sources.
“We see tremendous potential for the combined business both in the US and the international market and look forward to working closely with the Radcal team to continue the strong growth of its leading offering.”
IBA is a supplier of equipment and services in the field of proton therapy, which is considered to be the most advanced form of radiation therapy available.
With around 2,000 people worldwide, the company also provides dosimetry and quality assurance (QA) solutions in the fields of industrial sterilisation, and radiopharmaceuticals.
IBA is a certified B Corporation (B Corp), which means the company meets the highest standards of verified social and environmental performance.
The Belgian medical device company said that the acquisition will further strengthen its medical imaging quality assurance offering and its presence in the US market.
IBA Dosimetry president Jean-Marc Bothy said: “We are committed to providing the very best in medical imaging and radiotherapy quality assurance to our customers globally, contributing to our ultimate goal to treat more patients safely.
“Radcal’s growing product offering will enable us to reach new customers in the US and expand our presence in the Medical Imaging Quality Assurance market internationally.”